Abstract
Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have